Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table. Our biotech picks this week are making strides in fields such as immune-oncology, hematologic...
CytoKinetics, Inc. (NASDAQ: CYTK), a late-stage biopharmaceutical company, is developing therapeutics for the treatment of cardiovascular and neuromuscular diseases that are characterized by impaired muscle function such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) heart failure and hypertrophic cardiomyopathies (HCM). The Company announced preclinical...
Replimune group, Inc. (NASDAQ: REPL) is leveraging the power of its proprietary Immulytic platform to create a leading-edge oncolytic immunotherapy program that can generate a patient-specific local as well as systemic immune response. The therapies not only fight against the current cancer but also eliminate...
Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...
Cancer is the second leading cause of death in the U.S, next only to heart diseases. An estimated 1.7 million new cancer cases are likely to be diagnosed in 2019 in the U.S alone, with 606,880 Americans eventually succumbing to the disease, according to the...
Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical Company engaged in developing candidates for oncology, auto-immune and chronic pain, has announced the withdrawal of its application for oxycodegol (formerly NKTR-181), as it received adverse advisory committee decision from both Anesthetic and Analgesic Drug Products Advisory Committee, and...
Lexicon Pharmaceuticals (NASDAQ: LXRX), a biopharmaceutical company leveraging its proprietary Genome5000™ program to develop therapeutics for the treatment of disease such as diabetes, metabolism, oncology and neuropathic pain, announced that the Food and Drug Administration (FDA) has reiterated its rejection of the Company’s New Drug...
The American Cancer society estimates that in 2019, there will be around 22,530 new diagnoses of Ovarian Cancer and 13,980 women will succumb to the disease. It is the fifth largest cause for death in women, with over 1 in 78 chances of acquiring this...
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes the body’s immune system to attack healthy tissue causing inflammation, photosensitivity, oral ulcers, pleuritis, joint pain, arthritis, fever and a butterfly rash. In the long-run it can affect the kidneys, brain and heart as well....
Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,230 deaths every year as per an estimate by the American Cancer Society, these numbers are steadily rising over the years with approximately 96,480 new melanomas diagnosis being made each year....
